Compare Cytokinetics Inc (CYTK) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MGM Resorts International — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while MGM Resorts International trades at $30.3 (market cap $7.55B). The key difference: Cytokinetics Inc and MGM Resorts International are close in size by market cap, and MGM Resorts International pays a 0.03% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and MGM Resorts International for 91 Days on average.
| CYTK | MGM | |
|---|---|---|
Market Cap | $8.62B | $7.55B |
Volume | 2,594,626 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $50.69 |
52-Week Low | $54.76 | $30.00 |
Typical Hold Time | 19 Days | 91 Days |
Enterprise Value | $8.72B | $34.85B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
MGM Resorts International (MGM) trades at $30.00, down 1.77% on the day and facing bearish technical momentum despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $17.54B in 2025 but declining net margins to 1.17%. Recent market sentiment has been negatively impacted by the collapse of Barry Diller's $48.30 per share acquisition offer, though MGM is now exploring a potential bid for Diller's People Inc. Analyst consensus remains bullish with a $48.75 price target representing significant upside potential.
The stock presents a compelling value opportunity with attractive valuation metrics (P/E 18.19, P/S 0.45) and strong analyst support, but faces near-term headwinds from deal uncertainty and bearish technical signals. Key risks include execution challenges in potential M&A activity and ongoing margin pressure in the competitive gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
